Provided by Tiger Trade Technology Pte. Ltd.

CVRx, Inc.

4.95
-0.7400-13.01%
Post-market: 4.950.00000.00%18:29 EST
Volume:701.79K
Turnover:3.54M
Market Cap:129.74M
PE:-2.42
High:5.67
Open:5.60
Low:4.72
Close:5.69
52wk High:15.42
52wk Low:4.30
Shares:26.21M
Float Shares:17.96M
Volume Ratio:3.52
T/O Rate:3.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0436
EPS(LYR):-2.0436
ROE:-96.59%
ROA:-26.90%
PB:3.30
PE(LYR):-2.42

Loading ...

CVRx Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Feb 14

Piper Sandler Keeps Their Buy Rating on CVRx (CVRX)

TIPRANKS
·
Feb 13

CVRx price target lowered to $10 from $11 at Canaccord

TIPRANKS
·
Feb 13

CVRx Inc Q1 REV View $14.2 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Feb 13

CVRx Inc Outlook First Quarter Total Revenue Between $13.7 Mln and $14.7 Mln

THOMSON REUTERS
·
Feb 13

CVRx Q4 revenue rises 4%, beats expectations

Reuters
·
Feb 13

CVRx reports Q4 EPS (46c), consensus (44c)

TIPRANKS
·
Feb 13

CVRx Q4 EPS $(0.46) Misses $(0.44) Estimate, Sales $16.024M Beat $15.767M Estimate

Benzinga
·
Feb 13

CVRx Inc. FY2025 revenue rises 10% to USD 56.7 million

Reuters
·
Feb 13

BRIEF-CVRx Q4 Revenue USD 16.024 Million Vs. IBES Estimate USD 15.8 Million

Reuters
·
Feb 13

CVRx Q4 Gross Margin 86%

THOMSON REUTERS
·
Feb 13

CVRx Q4 Basic EPS USD -0.46

THOMSON REUTERS
·
Feb 13

Press Release: CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Dow Jones
·
Feb 13

Lake Street Reaffirms Their Buy Rating on CVRx (CVRX)

TIPRANKS
·
Feb 07

CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026

GlobeNewswire
·
Jan 30

CVRx (CVRX) Gets a Buy from Lake Street

TIPRANKS
·
Jan 23

Canaccord Genuity Sticks to Their Buy Rating for CVRx (CVRX)

TIPRANKS
·
Jan 23

CVRx Inc - Enrollment Is Expected to Begin in the First Half of 2026

THOMSON REUTERS
·
Jan 23

CVRx Inc - Primary Endpoint: All-Cause Mortality and Heart Failure Decompensation Events

THOMSON REUTERS
·
Jan 23

CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

GlobeNewswire
·
Jan 23